Correction to: ITGBL1 is a new immunomodulator that favors development of melanoma tumors by inhibiting natural killer cells cytotoxicity (Molecular Cancer, (2021), 20, 1, (12), 10.1186/s12943-020-01306-2)

Yann Cheli, Meri K. Tulic, Najla El Hachem, Nicolas Nottet, Arnaud Jacquel, Maeva Gesson, Thomas Strub, Karine Bille, Alexandra Picard-Gauci, Henri Montaudié, Guillaume E. Beranger, Thierry Passeron, Pierre Close, Corine Bertolotto, Robert Ballotti

Research output: Contribution to journalComment/debate

Abstract

Following the publication of the original paper [1], the authors found out that the supplementary material is incomplete. Thus, the publication of correction to notify the readers on the error. Updated supplementary file is provided in this article.

Original languageEnglish
Article number21
JournalMolecular Cancer
Volume20
Issue number1
DOIs
StatePublished - Dec 2021
Externally publishedYes

Fingerprint

Dive into the research topics of 'Correction to: ITGBL1 is a new immunomodulator that favors development of melanoma tumors by inhibiting natural killer cells cytotoxicity (Molecular Cancer, (2021), 20, 1, (12), 10.1186/s12943-020-01306-2)'. Together they form a unique fingerprint.

Cite this